Imugene(IUGNF)
$0.03-0.01 (-21.62%)
IUGNF
Imugene stock drug pipeline
$0.03
At close:-0.01 (-21.62%)
Imugene (IUGNF) Drug Pipeline
40 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Hydroxyurea, Cf33-Cd19 It Monotherapy, Cf33-Cd19 Iv Monotherapy, Cf33-Cd19 It Combination, Cf33-Cd19 Iv Combination, Blinatumomab | Solid Tumor, Adult | Phase I | Recruiting | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) | Sep 14, 2023 | ― |
| Pembrolizumab, Cf33-Hnis, Modified Folfox | Advanced Solid Tumor, Solid Tumor, Metastatic Cancer, Solid Tumor, Adult, Bile Duct Cancer, Cholangiocarcinoma, Solid Carcinoma | Phase I | Recruiting | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | Mar 22, 2022 | ― |
| Pembrolizumab, Imu-131, Ramucirumab Plus Paclitaxel | Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stomach Cancer, Cancer Of Stomach, Stomach Adenocarcinoma | Phase II | Terminated | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) | Mar 08, 2022 | ― |
| Atezolizumab, Standard Of Care Chemotherapy, Imu-201 (Administered As Pd1-Vaxx) - Regimen 1, Imu-201 (Administered As Pd1-Vaxx) - Regimen 2, Imu-201 (Administered As Pd1-Vaxx) - Regimen 3 | Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer Stage Iv, Non Small Cell Lung Cancer Stage Iiib, Squamous Non-Small-Cell Lung Cancer, Large Cell Carcinoma Lung, Adenocarcinoma Lung | Phase I | Active Not Recruiting | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer | May 10, 2020 | ― |
| Bendamustine, Cyclophosphamide, Fludarabine, Azer-Cel, Il-2 | Non-Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia | Phase I | Recruiting | Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL | Aug 20, 2018 | ― |
| Imu-131, Cisplatin And Either Fluorouracil (5-Fu) Or Capecitabine Or Oxaliplatin And Capecitabine. | Adenocarcinoma, Gastrointestinal Neoplasms | phase1AndPhase2 | Completed | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Jun 01, 2016 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Hydroxyurea, Cf33-Cd19 It Monotherapy, Cf33-Cd19 Iv Monotherapy, Cf33-Cd19 It Combination, Cf33-Cd19 Iv Combination, Blinatumomab | Phase I | Solid Tumor, Adult | Recruiting | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) | Sep 14, 2023 | ― |
| Pembrolizumab, Cf33-Hnis, Modified Folfox | Phase I | Advanced Solid Tumor, Solid Tumor, Metastatic Cancer, Solid Tumor, Adult, Bile Duct Cancer, Cholangiocarcinoma, Solid Carcinoma | Recruiting | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | Mar 22, 2022 | ― |
| Pembrolizumab, Imu-131, Ramucirumab Plus Paclitaxel | Phase II | Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stomach Cancer, Cancer Of Stomach, Stomach Adenocarcinoma | Terminated | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) | Mar 08, 2022 | ― |
| Atezolizumab, Standard Of Care Chemotherapy, Imu-201 (Administered As Pd1-Vaxx) - Regimen 1, Imu-201 (Administered As Pd1-Vaxx) - Regimen 2, Imu-201 (Administered As Pd1-Vaxx) - Regimen 3 | Phase I | Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer Stage Iv, Non Small Cell Lung Cancer Stage Iiib, Squamous Non-Small-Cell Lung Cancer, Large Cell Carcinoma Lung, Adenocarcinoma Lung | Active Not Recruiting | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer | May 10, 2020 | ― |
| Bendamustine, Cyclophosphamide, Fludarabine, Azer-Cel, Il-2 | Phase I | Non-Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia | Recruiting | Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL | Aug 20, 2018 | ― |
| Imu-131, Cisplatin And Either Fluorouracil (5-Fu) Or Capecitabine Or Oxaliplatin And Capecitabine. | phase1AndPhase2 | Adenocarcinoma, Gastrointestinal Neoplasms | Completed | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Jun 01, 2016 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Imugene Ltd (IUGNF) have in its pipeline
Imugene IUGNF is currently developing the following drugs: Hydroxyurea, Cf33-Cd19 It Monotherapy, Cf33-Cd19 Iv Monotherapy, Cf33-Cd19 It Combination, Cf33-Cd19 Iv Combination, Blinatumomab, Pembrolizumab, Cf33-Hnis, Modified Folfox, Pembrolizumab, Imu-131, Ramucirumab Plus Paclitaxel, Atezolizumab, Standard Of Care Chemotherapy, Imu-201 (Administered As Pd1-Vaxx) - Regimen 1, Imu-201 (Administered As Pd1-Vaxx) - Regimen 2, Imu-201 (Administered As Pd1-Vaxx) - Regimen 3, Bendamustine, Cyclophosphamide, Fludarabine, Azer-Cel, Il-2, Imu-131, Cisplatin And Either Fluorouracil (5-Fu) Or Capecitabine Or Oxaliplatin And Capecitabine.. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
